There are 2789 resources available
279P - Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01)
Presenter: Cristina Saura Manich
Session: ePoster Display
280P - Intracranial activity of trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients with active brain metastases: Results from the first stage of the phase II TUXEDO-1 trial
Presenter: Rupert Bartsch
Session: ePoster Display
281P - Prognostic impact of immune interactions in HER2+ and triple-negative breast cancer brain metastases
Presenter: Gaia Griguolo
Session: ePoster Display
282P - Methylthioadenosine phosphorylase (MTAP) genomic loss in ERBB2 amplified (amp) and mutated (mut) (ERBB2+) metastatic breast cancer (MBC)
Presenter: Abirami Sivapiragasam
Session: ePoster Display
283P - Treatment landscape of HER2-positive metastatic breast cancer (MBC): Results from the Austrian AGMT_MBC-Registry
Presenter: Simon Peter Gampenrieder
Session: ePoster Display
212P - HER2-low breast cancer: Evolution from primary tumor to residual disease after neoadjuvant treatment
Presenter: Federica Miglietta
Session: ePoster Display
213P - Predictive markers of cardiotoxicity associated with breast cancer treatment
Presenter: Ines Nogueira Costa
Session: ePoster Display
214P - Landscape of homologous recombination repair gene mutations in different molecular subtypes of breast cancer
Presenter: Yan Xu
Session: ePoster Display
215P - Somatic mutations and gene expression of neuroendocrine pathways in aggressive and nonaggressive breast cancer
Presenter: Kejia Hu
Session: ePoster Display
216P - Prognostic role of Ki67 cutoff and mPEPI score for neoadjuvant ‘chemotherapy’ in locally advanced HER2-negative ‘luminal’ breast cancer
Presenter: Mutlu Dogan
Session: ePoster Display